Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Suite 320
Lexington, MA 02421
July 25, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street N.E.
Washington, D.C. 20549
Attn: Dorrie Yale
| Re: | Aldeyra Therapeutics, Inc. |
| Registration Statement on Form S-3 (File No. 333-226266) |
Dear Ms. Yale:
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, Aldeyra Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:30 p.m. Eastern Time on Friday, July 27, 2018 or as soon thereafter as practicable.
The Company hereby authorizes Keith Scherer of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please provide a copy of the Commission’s order declaring the Registration Statement effective to Keith Scherer at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Keith Scherer at kscherer@gunder.com.
Thank you for your attention on this matter.
| Very truly yours,
Aldeyra Therapeutics, Inc. | ||
| By: | /s/ Todd C. Brady, M.D., Ph.D. | |
| Todd C. Brady, M.D., Ph.D. Chief Executive Officer | ||
| cc: | Keith Scherer, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP |